Welcome to our dedicated page for Io Biotech news (Ticker: IOBT), a resource for investors and traders seeking the latest updates and insights on Io Biotech stock.
IO Biotech, Inc. (Nasdaq: IOBT) is a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its T-win® platform. This news page aggregates company announcements, clinical updates, financial disclosures, and regulatory communications related to IO Biotech and its lead investigational cancer vaccine candidate, Cylembio® (IO102-IO103).
Readers can find coverage of clinical trial milestones, including data from the pivotal Phase 3 IOB-013/KN-D18 trial of Cylembio plus KEYTRUDA® (pembrolizumab) in advanced melanoma and Phase 2 basket trials in non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), and other solid tumors. News items also highlight long-term outcomes from earlier-phase studies, such as the MM1636 Phase 1/2 trial, and pre-clinical data for additional T-win platform candidates IO112 and IO170.
Investors and followers of IOBT can review regulatory and corporate updates, including the company’s reports on FDA interactions regarding Cylembio, workforce restructuring plans, and participation in major medical and investor conferences. Financial press releases provide quarterly results, operating expense trends, cash position commentary, and details on financing arrangements such as the European Investment Bank term loan facility and associated warrants.
This page is useful for tracking how IO Biotech communicates progress on its immune-modulatory cancer vaccine programs, interprets key efficacy and safety results, and describes its ongoing engagement with regulators and collaborators. For those monitoring IOBT stock or the broader immuno-oncology field, the news feed offers a centralized view of the company’s scientific presentations, trial readouts, and strategic business developments over time.
IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company focused on developing immune-modulatory cancer vaccines, has announced its participation in two upcoming investor conferences in New York.
The company will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025, at 7:45 am ET, featuring a fireside chat with CEO Mai-Britt Zocca, CFO Amy Sullivan, and CMO Qasim Ahmad. Additionally, CEO Mai-Britt Zocca will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025, at 8:00 am ET.
Webcasts of both presentations will be available in the Investors section of IO Biotech's website for 90 days following the events.
IO Biotech (Nasdaq: IOBT) reported Q2 2025 financial results and key developments for its cancer vaccine pipeline. The company's Phase 3 trial of Cylembio® plus KEYTRUDA® for first-line advanced melanoma treatment showed clinical improvement in progression-free survival, though narrowly missing statistical significance. The study involved 407 patients with unresectable or metastatic melanoma.
Financial highlights include a net loss of $26.2 million in Q2 2025, with cash and equivalents of $28.1 million as of June 30, 2025. The company secured additional funding through a €12.5 million second tranche from the European Investment Bank loan facility in July 2025, extending operations into Q1 2026.
IO Biotech plans to meet with the FDA this fall to discuss potential Biologics License Application submission for advanced melanoma treatment. Initial data from two Phase 2 trials is expected in H2 2025.
IO Biotech (NASDAQ: IOBT) announced topline results from its pivotal Phase 3 trial of Cylembio® plus KEYTRUDA® for first-line advanced melanoma treatment. While the combination showed clinical improvement in progression-free survival (19.4 months vs. 11.0 months), it narrowly missed statistical significance with HR=0.77 (p=0.056).
Notable findings include a profound effect in PD-L1 negative patients (16.6 vs. 3.0 months, HR: 0.54, p=0.006) and improved results in patients without prior anti-PD-1 treatment (24.8 vs. 11.0 months, HR: 0.74, p=0.037). The combination demonstrated a positive safety profile with no new safety signals. A trend toward improved overall survival was observed (HR=0.79), though data is not yet mature.
IO Biotech plans to meet with the FDA this fall to discuss potential regulatory submission.
IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company, has scheduled a conference call and webcast for August 11, 2025, at 8:30 AM ET to reveal topline results from its pivotal Phase 3 trial (IOB-013/KN-D18). The trial evaluates Cylembio, an investigational immune-modulatory cancer vaccine, in combination with KEYTRUDA® versus KEYTRUDA® alone for first-line treatment of advanced melanoma.
The study focuses on patients with unresectable or metastatic melanoma, with management hosting a live discussion of the results. A replay will be available on the company's website after the event.
IO Biotech (IOBT), a clinical-stage biopharmaceutical company focused on developing immune-modulatory therapeutic cancer vaccines, has announced its participation in two upcoming investor conferences. The company's leadership team, including CEO Mai-Britt Zocca, CFO Amy Sullivan, and CMO Qasim Ahmad, will participate in a fireside chat at the TD Cowen 6th Annual Oncology Summit on May 27, 2025. Additionally, Dr. Zocca will present at the Jefferies Global Healthcare Conference on June 4, 2025, where the team will also conduct one-on-one investor meetings.
IO Biotech (Nasdaq: IOBT) showcased its scientific leadership at the 2025 AACR Annual Meeting through an educational session on cancer vaccines. The company's scientific co-founder, Dr. Mads Hald Andersen, chaired and presented at the session, focusing on immune-modulatory vaccines (IMVs).
Dr. Andersen's presentation highlighted the dual mechanism of action of IO102-IO103, IO Biotech's most advanced therapeutic cancer vaccine. The vaccine targets both tumor cells and host immune suppressive cells by activating T cells against IDO+ and PDL1+ cells. Recent data suggests it can reprogram the tumor microenvironment (TME) through inflammatory cytokine induction and macrophage phenotypic changes, promoting a more immune-permissive environment.
IO Biotech (IOBT) presented new preclinical data for two cancer vaccine candidates at the AACR Annual Meeting 2025 in Chicago. The company showcased findings for:
1. IO102-IO103: Their lead therapeutic vaccine targeting IDO1 and PD-L1 demonstrated strong T-cell responses and unique tumor microenvironment modulation in mouse models, with effects distinct from conventional PD-1/PD-L1 inhibitors.
2. IO170: Their TGF-β-directed vaccine showed significant tumor growth inhibition in breast and prostate cancer models, increasing CD8+ T-cell density and reducing suppressive cells like M2 macrophages.
Both vaccines, developed using IO Biotech's T-win® platform, showed promising results in reshaping the tumor microenvironment to enhance anti-tumor immunity.
IO Biotech (IOBT) announced the acceptance of two abstracts for presentation at the 2025 AACR Annual Meeting in Chicago. The presentations will showcase new non-clinical data for their cancer vaccine candidates:
1. Data demonstrating how IO102-IO103, their lead candidate currently in Phase 3 trials for advanced melanoma, controls tumor growth through target-specific T-cell activation.
2. Preclinical data for IO170, their pipeline candidate targeting TGF-beta, showing promising antitumor activity.
Additionally, Dr. Mads Hald Andersen, the company's scientific co-founder, will chair and speak at an educational session on cancer vaccines, exploring the latest advances in cancer vaccine research.
IO Biotech (Nasdaq: IOBT) has been recognized as the 9th most innovative company in biotechnology on Fast Company's World's Most Innovative Companies of 2025 list. The clinical-stage biopharmaceutical company earned this distinction for its innovative approach to immune-modulatory cancer vaccines.
The company's T-win® platform develops off-the-shelf therapeutic cancer vaccines designed to target and kill both tumor cells and immune-suppressive cells in the tumor microenvironment. Their lead candidate, Cylembio®, is currently in:
- A global Phase 3 trial for advanced melanoma with primary endpoint readout expected in Q3 2025
- Phase 2 trials combining with pembrolizumab for non-small cell lung cancer and head and neck cancer
- Phase 2 trials as neoadjuvant and adjuvant treatment for resectable melanoma and head and neck cancer
The recognition by Fast Company highlights IO Biotech's potential to transform the oncology treatment paradigm with products designed to be available at diagnosis.
FAQ
What is the current stock price of Io Biotech (IOBT)?
What is the market cap of Io Biotech (IOBT)?
